Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

COMPARE results: Boston Scientific's second-generation Taxus Liberté paclitaxel-eluting stent "should no longer be used in everyday practice" because the device is inferior to Abbott's everolimus-eluting Xience V, Dutch researchers assert in an article published online in The Lancet Jan. 8. One-year results of the 1,800-patient COMPARE study, conducted by Elvin Kedhi, Maasstad Ziekenhuis, Rotterdam, et al., were first unveiled at the Transcatheter Cardiovascular Therapeutics conference in September (1"The Gray Sheet" Sept. 28, 2009). The primary endpoint, a composite of all-cause mortality, myocardial infarction and target vessel revascularization, occurred in 6% of patients in the Xience V arm versus 9% of the Taxus subjects. The COMPARE results represent a double-edged sword for Boston Scientific - the company also markets the private-label version of Xience, called Promus, and thus benefits from positive Xience data. However, bad press for Taxus could make it difficult for Boston Scientific to stabilize the brand's declining share of the drug-eluting stent market, Wachovia analyst Larry Biegelsen pointed out Jan. 8. J.P. Morgan's Michael Weinstein estimates Promus will be the biggest beneficiary of Taxus' lost share of the DES segment, increasing its share from 27.6% in the fourth quarter of 2009 to 31.6% in 2010. Meanwhile, Xience's share is expected to remain flat at 30%-31%, he said

You may also be interested in...



Boston Scientific Plans Taxus Element FDA Submission In Next Three Months

Boston Scientific plans to submit a PMA for its third-generation platinum-chromium Taxus Element stent to FDA by June, relying on pivotal trial data reported March 15 at the American College of Cardiology meeting in Atlanta

Boston Scientific Plans Taxus Element FDA Submission In Next Three Months

Boston Scientific plans to submit a PMA for its third-generation platinum-chromium Taxus Element stent to FDA by June, relying on pivotal trial data reported March 15 at the American College of Cardiology meeting in Atlanta

ACC 2010: Transcatheter Mitral Valve Repair Data Among Expected Highlights

A substantial 2009 acquisition by Abbott could be validated and the prospects for Boston Scientific's future drug-eluting stent portfolio weighed from data set to be presented later this month at the American College of Cardiology annual conference

Related Content

Topics

UsernamePublicRestriction

Register

MT028366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel